Abstract 827P
Background
An expanding number of genes predisposing to hematologic malignancies are being discovered by next-generation sequencing (NGS) technology. The 5th edition of the World Health Organization and International Consensus Classification revised their classification of hematologic neoplasms with germline predisposition acknowledging this development. We aimed to identify the mutational spectrum of germline predisposition in hematologic malignancies from Korean patients.
Methods
The study included 444 patients tested for hematologic malignancy panel testing at Pusan National University Yangsan Hospital from January 2019 to December 2022. The assay consisted of 200 genes related to hematologic malignancies and was performed with NGS on genomic DNA extracted from bone marrow specimens or peripheral blood. We identified potential germline variants by retrospective analysis of NGS results. Variant allele frequency > 0.3 of pathogenic or likely pathogenic variants in a known germline predisposition gene was considered potential germline variants. We could not confirm each variant's germline status due to the absence of cultured skin fibroblast specimens.
Results
Thirty-seven (8.33%) patients harbored 38 potential germline variants. DDX41 (21.62%, 8 patients), RUNX1 (10.81%, 4 patients), GATA2 (10.81%, 4 patients), and PAX5 (10.81%, 4 patients) were the most common genes. One patient had 2 variants in the SBDS gene, a compound heterozygote. Frameshift (18 variants, 47.37%) and missense (10 variants, 26.32%) were the main proportion of the 38 potential germline variants.
Conclusions
We found that DDX41, RUNX1, GATA2, and PAX5 are the most common genes in potential germline variants in hematologic malignancies in Korea. This study provides insight into the pathophysiology of germline predisposition in hematologic malignancies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
978P - Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)
Presenter: Claudia Fulgenzi
Session: Poster session 18
979P - Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ+BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Phase IIIb ATHECA
Presenter: Maria Elisa Reig Monzon
Session: Poster session 18
980P - Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma
Presenter: Young Mi Hong
Session: Poster session 18
981P - The response of portal vein tumoral thrombosis to moderately hypo-fractionated radiotherapy using intensity modulated radiotherapy
Presenter: Ahmad Abdel-Azeez
Session: Poster session 18
982P - Transarterial chemoembolization with idarubicin versus epirubicin for hepatocellular carcinoma: An interim analysis of a multicentre, randomized controlled phase III trial
Presenter: Zhewei Zhang
Session: Poster session 18
983P - Safety and efficacy of durvalumab plus hepatic artery infusion chemotherapy in HCC with severe portal vein tumor thrombosis (Vp3/4) – the DurHope study
Presenter: Ming Zhao
Session: Poster session 18
984P - Comparative study of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma: A nationwide cohort study
Presenter: Jo Kook Lee
Session: Poster session 18
987P - Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
Presenter: Wonseok Kang
Session: Poster session 18
988P - Burden of primary liver cancer in the Middle East and North Africa Region from 1990 to 2019
Presenter: Ahmed Hafez Allam
Session: Poster session 18